Echo Therapeutics Announces Full Exercise of Over-Allotment Option

PHILADELPHIA, Dec. 26, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. ECTE, a company developing its needle-free Symphony^® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 480,000 additional common shares, at a public offering price of $0.95 per share, in connection with its previously announced underwritten public offering of 3,200,000 shares of common stock, bringing the total gross proceeds from the offering to $3,496,000, before deducting the underwriting discount and other offering expenses payable by Echo. 

(Logo:  http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. acted as the sole book-running manager for the offering.

Feltl and Company acted as co-manager for the offering.

The offering is being made pursuant to a shelf registration statement that Echo previously filed with the Securities and Exchange Commission (the "SEC") and which is effective.  A final prospectus supplement and accompanying base prospectus has been filed with SEC and is available on the SEC's website at www.sec.gov.  Electronic copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18^th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com. 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude^® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements, including statements regarding Echo's proposed public offering.  These statements are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to general market conditions and the other risks and uncertainties identified and described in more detail in Echo's filings with the Securities and Exchange Commission.   Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com                                       

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.